Gita Suneja

Positions:

Associate Professor of Radiation Oncology

Radiation Oncology
School of Medicine

Associate Research Professor of Global Health

Duke Global Health Institute
Institutes and Provost's Academic Units

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2008

Brown University

Intern, Internal Medicine

University of Pennsylvania School of Medicine

Resident, Radiation Oncology

University of Pennsylvania School of Medicine

Chief Resident, Radiation Oncology

University of Pennsylvania School of Medicine

Clinical Instructor, Radiationoncology

University of Pennsylvania School of Medicine

Assistant Professor, Radiation Oncology

University of Utah School of Medicine

Grants:

Publications:

Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival.

OBJECTIVES: Uterine carcinosarcoma (UCS) is a rare and aggressive cancer with poor survival. Our purpose was to evaluate the patterns-of-care and overall survival (OS) benefit of adjuvant chemoradiation (aCRT) compared with adjuvant chemotherapy (aCT) among UCS patients. METHODS: A query was made in the National Cancer Database to identify patients with UCS diagnosed between 2004 and 2012. Factors predictive of OS were determined using univariate and multivariate Cox regression analysis, as well as Kaplan-Meier and log-rank analysis. Propensity-score matching was employed to decrease the potential influence of selection bias. RESULTS: A total of 3538 patients were identified for analysis, consisting of 1787 patients (50.5%) receiving aCT and 1751 (49.5%) receiving aCRT. The median age of patients was 65 years. The majority of patients in our cohort were white (68.6%), on Medicare insurance (47.9%), with >5 cm tumor size (59.9%), and received a lymph node surgery (87.9%). The following factors were predictive of aCRT use: undergoing lymph node surgery (odds ratio, 1.59, P=0.01), and FIGO stage II (odds ratio, 1.71, P=0.01). Median survival for the aCT and aCRT groups was 24 months and 31.3 months, respectively. When compared with aCT alone, aCRT was associated with a benefit in OS on multivariate analysis (hazard ratio, 0.65, P<0.01). CONCLUSIONS: When compared with aCT alone, the use of aCRT in UCS patients was associated with a significant OS benefit. Multiple demographic and clinical factors significantly influence the choice of adjuvant therapy in this setting.
Authors
Odei, B; Boothe, D; Suneja, G; Werner, TL; Gaffney, DK
MLA Citation
Odei, Bismarck, et al. “Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival..” Am J Clin Oncol, vol. 41, no. 8, Aug. 2018, pp. 784–91. Pubmed, doi:10.1097/COC.0000000000000360.
URI
https://scholars.duke.edu/individual/pub1169887
PMID
28121642
Source
pubmed
Published In
American Journal of Clinical Oncology
Volume
41
Published Date
Start Page
784
End Page
791
DOI
10.1097/COC.0000000000000360

IMRT Utilization Rates for Treatment of Intact Cervical Cancer: A National Cancer Database Analysis

Authors
MLA Citation
Chino, F., et al. “IMRT Utilization Rates for Treatment of Intact Cervical Cancer: A National Cancer Database Analysis.” International Journal of Radiation Oncology*Biology*Physics, vol. 99, no. 2, Elsevier BV, 2017, pp. E285–86. Crossref, doi:10.1016/j.ijrobp.2017.06.1284.
URI
https://scholars.duke.edu/individual/pub1284419
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
99
Published Date
Start Page
E285
End Page
E286
DOI
10.1016/j.ijrobp.2017.06.1284

Chemoradiation Versus Chemotherapy or Radiation Alone in Stage III Endometrial Cancer: Patterns of Care and Impact on Overall Survival

Authors
Boothe, D; Orton, A; Odei, B; Suneja, G; Werner, T; Gaffney, DK
MLA Citation
Boothe, D., et al. “Chemoradiation Versus Chemotherapy or Radiation Alone in Stage III Endometrial Cancer: Patterns of Care and Impact on Overall Survival.” International Journal of Radiation Oncology Biology Physics, vol. 96, no. 2, 2016, pp. E286–E286. Wos-lite, doi:10.1016/j.ijrobp.2016.06.1344.
URI
https://scholars.duke.edu/individual/pub1162879
Source
wos-lite
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
96
Published Date
Start Page
E286
End Page
E286
DOI
10.1016/j.ijrobp.2016.06.1344

Risk of Secondary Malignancies after Radiation Therapy for Breast Cancer: Comprehensive Results

Authors
Burt, LM; Ying, J; Poppe, MM; Suneja, G; Gaffney, DK
MLA Citation
Burt, L. M., et al. “Risk of Secondary Malignancies after Radiation Therapy for Breast Cancer: Comprehensive Results.” International Journal of Radiation Oncology*Biology*Physics, vol. 93, no. 3, Elsevier BV, 2015, pp. S107–08. Crossref, doi:10.1016/j.ijrobp.2015.07.258.
URI
https://scholars.duke.edu/individual/pub1150247
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
93
Published Date
Start Page
S107
End Page
S108
DOI
10.1016/j.ijrobp.2015.07.258

Cancer in Botswana: A Prospective Cohort Study of Cancer Type, Treatment, and Outcomes

Authors
Suneja, G; Dryden-Peterson, S; Boyer, M; Musimar, Z; Nsingo-Bvochora, M; Ramogola-Masire, D; Medhin, H; Bekelman, J; Lockman, S; Rebbeck, T
MLA Citation
Suneja, G., et al. “Cancer in Botswana: A Prospective Cohort Study of Cancer Type, Treatment, and Outcomes.” International Journal of Radiation Oncology*Biology*Physics, vol. 87, no. 2, Elsevier BV, 2013, pp. S492–93. Crossref, doi:10.1016/j.ijrobp.2013.06.1302.
URI
https://scholars.duke.edu/individual/pub1150234
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
87
Published Date
Start Page
S492
End Page
S493
DOI
10.1016/j.ijrobp.2013.06.1302